Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;61(6):1700-1704.
doi: 10.1111/trf.16358. Epub 2021 Mar 11.

Platelet transfusion refractoriness and anti-HLA immunization

Lucie Blandin  1 , Aurore Dougé  1   2 , Amandine Fayard  3 , Jacques-Olivier Bay  3   4 , Guillaume Berlie  5 , Bruno Pereira  6 , Richard Lemal  1   4 , Paul Rouzaire  1   4
Affiliations

Platelet transfusion refractoriness and anti-HLA immunization

Lucie Blandin et al. Transfusion. 2021 Jun.

Abstract

Platelet transfusion refractoriness (PTR), defined as an unsatisfactory post-transfusion platelet count increment, is a common complication of patients receiving multiple transfusions. Different strategies are described in the management of PTR. In this work, we demonstrate the efficacy of the detection and identification of anti-HLA antibodies in the recipient using a threshold of 3000 mean fluorescence intensity (MFI), and the seek of donors not expressing HLA antigens against which the patient is immunized.

Keywords: MFI threshold; anti-HLA immunization; platelet transfusion refractoriness.

PubMed Disclaimer

References

REFERENCES

    1. Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337:1861-9.
    1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348-60.
    1. Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74(4):185-9.
    1. Forest SK, Hod EA. Management of the platelet refractory patient. Hematol Oncol Clin North Am. 2016;30(3):665-77.
    1. Linjama T, Niittyvuopio R, Tuimala J, Pyörälä M, Rintala H, Rimpiläinen J, et al. Platelet donor selection for HLA-immunised patients; the impact of donor-specific HLA antibody levels: Platelet donor selection for HLA-immunised patients. Transfus Med. 2017;27(5):375-83.

LinkOut - more resources